Olodanrigan sodium (EMA401; PD126055; EMA-401), a novel, orally bioavailable, peripherally restricted and highly selective AT2R (angiotensin II type 2 receptor) antagonist, can be potentially used for treatment of postherpetic neuralgia (PHN). Inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons. It is being developed as a neuropathic pain therapeutic agent.

纯度：≥98%

CAS：1316755-17-5